What's Going On With Pfizer Stock Today?
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) is expected to report a Q4 2023 EPS loss of $(0.22) and revenues of $14.25 billion. The company's FY24 revenue forecast includes contributions from the Seagen acquisition, with adjusted EPS guidance lower than consensus. Pfizer's obesity drug trial showed efficacy but had high dropout rates due to side effects. Additionally, a former Pfizer employee was convicted of securities fraud. PFE shares dropped 1.69% in premarket trading.
January 25, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer anticipates a Q4 EPS loss and lower FY24 EPS guidance than consensus. Its obesity drug trial had high dropout rates, affecting stock sentiment. A former employee's fraud conviction may also impact reputation.
The anticipated Q4 EPS loss and lower FY24 guidance compared to consensus are likely to negatively impact investor sentiment in the short term. The high dropout rates in the obesity drug trial suggest potential issues with the drug's market viability, which could further dampen investor confidence. The conviction of a former employee for securities fraud, while not directly related to Pfizer's operations, could have a minor negative impact on the company's reputation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100